the primary of a number of biotechs to record their shares this week, rocketed as a lot as 571% Tuesday.
The inventory opened at $29, almost six instances the IPO worth, and peaked at $33.55. Shares modified arms in noon buying and selling at $14.20, up 184% from the supply worth.
Alzamend Neuro (ticker: ALZN) raised $12.5 million late Monday after promoting 2.5 million shares at $5 every. Spartan Capital Securities is underwriter on the deal.
More than 10 biotechs, together with Ambrx, Century Therapeutics and Cyteir Therapeutics, are anticipated to make their public equities market debuts this week. The most well-known firm is ATAI Life Sciences, a startup that goals to make use of psychedelic medicine to deal with psychological sickness. Thiel Capital, the funding agency from
is an investor.
Founded in 2016, Alzamend is creating merchandise to deal with neurodegenerative illnesses and psychiatric problems. Its lead product candidate, AL001, is an ionic cocrystal of lithium (an improved lithium formulation) that’s used to deal with Alzheimer’s, in addition to different neurodegenerative illnesses and psychiatric problems, a prospectus mentioned.
Alzamend plans to hunt approval from the U.S. Food and Drug Administration to commercialize AL001. The firm has began the method of getting ready an Investigational New Drug software which it plans to submit this month.
Like most biotechs, Alzamend hasn’t generated any income. Losses widened to about $3.8 million for the 9 months ended Jan. 31 from $3.2 million in losses for a similar interval in 2020, a prospectus for the deal said.
Write to [email protected]